Description
Ribostamycin was found in the culture broth of Streptomyces ribosidificus by Meiji Seika Kaisha in 1970 in the course of screening aminoglycoside antibiotics. It is structurally related to neomycin but lacks the diaminoidose (glucose) moiety substituted on the ribose moiety. Ribostamycin is much less toxic than neomycin and shows strong activity against a variety of gram-positive and gram-negative bacteria, except Pseudomonas aeruginosa. It is used parenterally for therapy of urinary tract, respiratory tract, surgical, and other infections.
Uses
Ribostamycin (Vistamycin) is a broad-spectrum aminoglycoside antibiotic. Ribostamycin is effective against Gram-Negative and Gram-Positive bacterial infection. Ribostamycin also inhibits the chaperone activity of PDI[1][2].
Definition
ChEBI: An amino cyclitol glycoside that is 4,6-diaminocyclohexane-1,2,3-triol having a 2,6-diamino-2,6-dideoxy-alpha-D-glucosyl residue attached at position 1 and a beta-D-ribosyl residue attache
at position 2. It is an antibiotic produced by Streptomyces ribosidificus (formerly S. thermoflavus).
Mechanism of action
Ribostamycin (SF-733) is produced by
Streptomyces ribosidificus. The free base is crystallized
from methanol solution. The structure
has been determined by chemical methods and
total synthesis has been undertaken .
in vivo
Ribostamycin (40 mg/kg, intramuscular injection, per day for 14 days) causes little nephrotoxicity in rats(evaluated by urinalysis)[5].
References
[1] Zheng T, et al. Linear self-assembly formation between gold nanoparticles and aminoglycoside antibiotics. Colloids Surf B Biointerfaces. 2018 Apr 1;164:185-191. DOI:
10.1016/j.colsurfb.2018.01.027[2] Hunfeld KP, et al. In vitro activity of mezlocillin, meropenem, aztreonam, vancomycin, teicoplanin, ribostamycin and fusidic acid against Borrelia burgdorferi. Int J Antimicrob Agents. 2001 Mar;17(3):203-8. DOI:
10.1016/s0924-8579(00)00342-3[3] Horibe T, et al. Ribostamycin inhibits the chaperone activity of protein disulfide isomerase. Biochem Biophys Res Commun. 2001 Dec 21;289(5):967-72. DOI:
10.1006/bbrc.2001.6105[4] Kong J, et al. Exploration of Antibiotic Activity of Aminoglycosides, in Particular Ribostamycin Alone and in Combination With Ethylenediaminetetraacetic Acid Against Pathogenic Bacteria. Front Microbiol. 2020 Jul 29;11:1718. DOI:
10.3389/fmicb.2020.01718[5] Kitasato I, et al. Comparative nephrotoxicity of ribostamycin and gentamicin in rats evaluated by urinalysis. Drugs Exp Clin Res. 1989;15(6-7):273-89. PMID:2591299
